| 1 | sit amet consectetur adipiscing | | | | | | | 4 | 0.44% |
| 2 | dolor sit amet consectetur | | | | | | | 4 | 0.44% |
| 3 | ipsum dolor sit amet | | | | | | | 4 | 0.44% |
| 4 | amet consectetur adipiscing eli | | | | | | | 3 | 0.33% |
| 5 | lorem ipsum dolor sit | | | | | | | 3 | 0.33% |
| 6 | consectetur adipiscing eli title | | | | | | | 2 | 0.22% |
| 7 | assessments el regulatory support | | | | | | | 2 | 0.22% |
| 8 | method development and validation | | | | | | | 2 | 0.22% |
| 9 | support materials selection lifecycle | | | | | | | 2 | 0.22% |
| 10 | regulatory support materials selection | | | | | | | 2 | 0.22% |
| 11 | el regulatory support materials | | | | | | | 2 | 0.22% |
| 12 | extractables and leachables project | | | | | | | 2 | 0.22% |
| 13 | 44 0 1223 756577 | | | | | | | 2 | 0.22% |
| 14 | within the pharmaceutical industry | | | | | | | 2 | 0.22% |
| 15 | title lorem ipsum dolor | | | | | | | 2 | 0.22% |
| 16 | graham worked for mylan | | | | | | | 1 | 0.11% |
| 17 | delivery of el support | | | | | | | 1 | 0.11% |
| 18 | to a growing portfolio | | | | | | | 1 | 0.11% |
| 19 | a growing portfolio of | | | | | | | 1 | 0.11% |
| 20 | growing portfolio of inhaled | | | | | | | 1 | 0.11% |
| 21 | portfolio of inhaled and | | | | | | | 1 | 0.11% |
| 22 | of inhaled and biosimilar | | | | | | | 1 | 0.11% |
| 23 | inhaled and biosimilar products | | | | | | | 1 | 0.11% |
| 24 | development registration and into | | | | | | | 1 | 0.11% |
| 25 | and biosimilar products through | | | | | | | 1 | 0.11% |
| 26 | on the delivery of | | | | | | | 1 | 0.11% |
| 27 | registration and into commercialization | | | | | | | 1 | 0.11% |
| 28 | and into commercialization during | | | | | | | 1 | 0.11% |
| 29 | into commercialization during this | | | | | | | 1 | 0.11% |
| 30 | commercialization during this time | | | | | | | 1 | 0.11% |
| 31 | his responsibilities included oversight | | | | | | | 1 | 0.11% |
| 32 | responsibilities included oversight of | | | | | | | 1 | 0.11% |
| 33 | the delivery of el | | | | | | | 1 | 0.11% |
| 34 | project teams on the | | | | | | | 1 | 0.11% |
| 35 | teams on the delivery | | | | | | | 1 | 0.11% |
| 36 | extractable and leachable specialist | | | | | | | 1 | 0.11% |
| 37 | for mylan for 4 | | | | | | | 1 | 0.11% |
| 38 | mylan for 4 years | | | | | | | 1 | 0.11% |
| 39 | for 4 years as | | | | | | | 1 | 0.11% |
| 40 | 4 years as their | | | | | | | 1 | 0.11% |